AMERICAN JOURNAL OF GASTROENTEROLOGY美国胃肠病学杂志
AMERICAN JOURNAL OF GASTROENTEROLOGY(英文缩写 AM J GASTROENTEROL),ISSN 0002-9270,eISSN 1572-0241,中文译名:美国胃肠病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 12.045 | Q1 |
| 2022 | 9.800 | Q1 |
| 2023 | 8.000 | Q1 |
| 2024 | 7.600 | Q1 |
| 2025 | 8.500 | Q1 |
AMERICAN JOURNAL OF GASTROENTEROLOGY 最新收录文献
-
1. ACG Clinical Guideline: Preventive Care for Patients With Cirrhosis.
1. ACG临床指南：肝硬化患者的预防性护理PMID:日期:2026-10-05Cirrhosis affects more than 2 million Americans and drives substantial healthcare utilization, impaired quality of life, and mortality. Because early-stage disease carries a favorable prognosis and decompensated patients can recompensate, systematic delivery of preventive care is essential. Under the auspices of the American College of Gastroenterology Practice Parameters Committee, a writing group of hepatology experts and 2 Grading of Recommendations, Assessment, Development, and Evaluation methodologists developed PICO questions, conducted librarian-assisted searches of PubMed, Embase, and the Cochrane Library, and prioritized systematic reviews, meta-analyses, and randomized trials. The resulting guidance comprises 18 Grading of Recommendations, Assessment, Development, and Evaluation-assessed recommendations and 6 key concept statements spanning 4 domains: prevention of cirrhosis-specific complications, infection prevention, lifestyle factors, and non-liver-specific conditions. Strong recommendations include carvedilol or variceal ligation of high-risk esophageal varices, semiannual hepatocellular carcinoma surveillance, hepatitis A testing and vaccination, influenza, severe acute respiratory syndrome coronavirus 2, respiratory syncytial virus immunization, and smoking-cessation counseling. Conditional recommendations address lactulose for minimal hepatic encephalopathy, adjunctive rifaximin after hospitalization, short-course antibiotic prophylaxis for upper gastrointestinal bleeding, postdischarge behavioral therapy for alcohol use disorder, dietitian-guided nutrition, structured exercise, and bisphosphonates for osteoporosis. Most evidence was of low certainty. We provide an implementation framework of education, stakeholder engagement, and practice integration to translate these recommendations into routine care.
-
3. Correction to: Spatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus.
3. 更正：Barrett食管患者中基于风险分层的表观遗传学生物标志物检测的时空研究PMID:日期:2026-09-25该文献暂无摘要。
-
5. Global Paid and Unpaid Productivity Losses Due to Gastrointestinal Cancer Mortality.
PMID:日期:2026-09-22Gastrointestinal (GI) cancers contribute substantially to premature mortality, yet their full economic burden, including unpaid work, remains underquantified. We aimed to estimate global productivity losses attributable to GI cancer mortality, considering paid and unpaid work. Years of productive life lost (YPLL) were calculated using data from GLOBOCAN for GI cancer among working-age individuals (15-64 years) across 185 countries. Paid productivity losses were estimated using the human capital approach, while unpaid work was valued via the opportunity cost method. Country-specific wages, labor force participation, and time allocated to unpaid tasks informed these estimates. In 2022, GI cancers caused 1.16 million deaths among adults. The estimated global productivity loss totaled $177.81 billion (United States Dollars; 31.4% of all cancer-related productivity losses). Paid labor accounted for $102.79 billion (57.81%), and unpaid work contributed $75.02 billion (42.19%). By cancer site, losses were highest for liver ($50.45 billion; 28.4%) and colorectal cancer ($49.53 billion; 27.9%). Eastern Asia experienced the largest losses ($67.62 billion). Very-high Human Development Index (HDI) countries accounted for the largest absolute productivity loss ($92.13 billion) and had the highest proportion of losses attributable to unpaid work (45%). Sex-specific analyses indicated that paid work dominated male losses (65%), while unpaid work dominated female losses (59%). GI cancer mortality causes major global productivity losses; over 40% stems from unpaid work that is often missed by standard estimates and disproportionately borne by females. Better measurement of unpaid work is crucial to developing equitable, gender-responsive cancer policies and healthcare investments worldwide.
-
6. Alcohol-Use Trajectories and Major Adverse Liver Outcomes in MetALD: A Nationwide Longitudinal Cohort Study.
6. MetALD患者的酒精使用轨迹与主要不良肝脏结局：一项全国性纵向队列研究PMID:日期:2026-09-18Alcohol contributes to the progression of steatotic liver disease. However, in individuals with MetALD, the impact of changes in drinking behavior on disease progression remains unclear. We investigated whether longitudinal changes in alcohol consumption were associated with the risk of major adverse liver outcomes (MALO) in people with MetALD. Data were obtained from the Korean National Health Screening Program. Adults with MetALD who completed three screening examinations (2009-2010, 2011-2012, and 2013-2014) were included (n = 85,554). Participants were categorized by alcohol consumption trajectories: Group 1 (sustained consumption), Group 2 (fluctuating consumption), and Group 3 (consistent reduction). The primary outcome was MALO, with cardiovascular death treated as a competing risk. Changes in cardiometabolic risk factors from baseline to the last examination were also evaluated. Over a median follow-up of 10.1 years, 32.9%, 34.6%, and 32.4% of participants were classified into Groups 1, 2, and 3, respectively. Groups 2 and 3 had lower MALO risks than Group 1 (adjusted subdistribution hazard ratios (95% confidence intervals), 0.80 (0.71-0.91) and 0.70 (0.61-0.79), respectively; both P <0.001). Compared with Group 1, Group 3 had higher rates of resolution of impaired fasting glucose, hypertriglyceridemia, and hypertension. Alcohol use in MetALD was highly dynamic, and hepatic risk was better captured using longitudinal drinking trajectories. Both intermittent and consistent alcohol reduction were associated with lower MALO risk, with a stronger association for consistent reduction. Consistent reduction was also accompanied by favorable changes in selected cardiometabolic risk factors.
-
8. Long-term Outcomes After Endoscopic Resection for pMM/SM1 Esophageal Cancer: A Multicenter Prospective Cohort Study.
PMID:日期:2026-09-18The optimal management of esophageal cancer with muscularis mucosae or shallow submucosal invasion (post-endoscopic resection [ER] pMM/SM1 cancer) remains controversial. Evidence is largely retrospective, and prospective data are lacking. This study enrolled patients with squamous cell carcinoma (SCC) or esophageal adenocarcinoma (EAC) diagnosed as post-ER pMM/SM1 cancer. Outcomes included overall survival, metastatic recurrence, local recurrence, and second primary esophageal cancer. Overall, 385 patients were enrolled, including 315 with SCC and 70 with EAC. Five-year overall survival was 92.3% (95% Confidence interval [CI], 88.8%-94.8%) for SCC and 94.2% (95% CI, 85.4%-97.8%) for EAC. Among post-ER lymphovascular invasion (LVI)-negative patients managed without additional treatment, 5-year survival rates were 94.0% (95% CI, 90.2%-96.4%) for SCC and 93.3% (95% CI, 83.5%-97.5%) for EAC. Cumulative metastatic recurrence rates for LVI-negative SCC were 6.3% (95% CI, 3.0%-12.6%) for pMM and 10.5% (95% CI, 2.6%-33.7%) for pSM1 disease, whereas corresponding rates for EAC were 2.2% (95% CI, 0.3%-13.9%) and 0.0% (95% CI could not be calculated). In LVI-negative SCC, lesion size and macroscopic appearance were independent predictors of metastatic recurrence: type 0-II lesions ≤30 mm had a low cumulative metastatic recurrence rate of 2.9% (95%CI, 1.1%-7.5%). The 5-year cumulative incidence of second primary esophageal cancer was 25.8% for SCC and 3.6% for EAC. Post-ER pMM/SM1 esophageal cancer is associated with excellent long-term survival. Surveillance is a reasonable option for many LVI-negative cases, although additional treatment may be considered for selected higher-risk patients.
-
9. Baseline characteristics of a prospective, multi-center study on the natural history of compensated cirrhosis: the Liver Cirrhosis Network.
9. 一项关于代偿性肝硬化自然史的前瞻性多中心研究的基线特征：肝硬化网络PMID:日期:2026-09-18该文献暂无摘要。
-
10. Life expectancy and changing causes of mortality in familial adenomatous polyposis (FAP).
PMID:日期:2026-09-18The impact of modern management on life expectancy in familial adenomatous polyposis (FAP) remains sparsely reported, and recent treatment effects on disease-related causes of death are unclear. This study provides an updated assessment of life expectancy and mortality causes. Patients born after January 1935 were identified from a prospectively maintained registry with supplementary clinical record review. Retrospective life table analysis compared mortality with a matched UK Office for National Statistics population. Causes of death were analysed by era and stratified by presentation type - newly presenting patients versus screen-detected relatives identified through family screening. Among 1917 patients with FAP, 364 deaths occurred versus 28 expected in the general population. Screen-detected relatives had consistently lower mortality, comparable to the general population (median SMR 0.66; SMR <1 throughout), whereas overall mortality was markedly higher in the unselected cohort (median SMR 11.09; p < 0.01). Newly presenting patients showed persistently elevated mortality across most birth cohorts.Colorectal disease remained the leading cause of death but declined significantly over time (64% pre-2001 to 31% post-2013; p < 0.01). Conversely, deaths from duodenal (3% to 12%; p < 0.01) and gastric disease (1% to 8%; p < 0.01), as well as non-FAP-related causes, increased. Screen-detected relatives had fewer colorectal deaths, particularly in earlier eras, but proportionally more duodenal and non-FAP-related deaths. Recent FAP cohorts now have mortality comparable to the general population. Although colorectal mortality has declined, gastroduodenal and non-FAP-related causes have increased, underscoring the need for continued surveillance and broader long-term management strategies.